Interim Report 2019

| Investor News

1st half-year 2019 of MPH Health Care AG: Investment companies develop according to plan and net asset value (NAV) of EUR 5.86 significantly above current share price

Berlin, 29. August 2019. The net asset value (NAV) of MPH Health Care AG (ISIN: DE000A0L1H32) was EUR 5.86 per share at the end of the first half of 2019, well above the current share price (Xetra closing price 28 August: EUR 3.89). Due to the continuing good results of the investments, MPH again distributed a dividend of 20 cents per share in July 2019. This corresponds to a dividend yield of 5,1%.

MPH’s listed and significant equity investments developed according to plan in the first half of 2019:

CR Capital Real Estate AG has increased its dividend for the 2018 financial year by 50% to EUR 1.50 per share and also resolved to issue new no-par value shares (bonus shares) at a ratio of 1:1. In the first six months of the current year, the company continued its positive business development. Sales amounted to EUR 6.32 million (H1/2018: EUR 12.83 million). The real estate company significantly increased its net income for the first half of the year from EUR 2.10 million to EUR 3.47 million. Currently, two projects are in the construction phase and others are in concrete development. For 2019 as a whole, the company expects earnings growth of around 30 percent. In addition to its positive operating performance, CR Capital Real Estate has expanded its business model in recent months. In the future, social housing will be another focus area. Thanks to its proven price-conscious design, CR is well placed to enter the social housing segment and create added value for both tenants and shareholders.

At its Annual General Meeting, M1 Kliniken AG approved the distribution of a dividend for 2018 of EUR 0.30 per share. Demand for the medical aesthetic services of the M1 Group continued to develop positively in the first half of 2019. Group sales rose from EUR 28.9 million to EUR 32.9 million. Germany’s market leader in the field of beauty medicine is profiting more and more from the investments made in recent years. The growth driver in the first half of the year was the strong-margin core segment “Beauty”, whose sales increased by more than 40 percent to EUR 20.3 million. Earnings before taxes (EBT) rose in the reporting period by 21 percent to EUR 5.2 million. In addition to the positive operating development, the M1 Group also set the course for further growth in Germany and abroad in the reporting period. Four further specialist centres were opened until end of July. In addition, treatment capacities were expanded at several German locations. The M1 Group has already established cosmetic laser treatments in ten beauty centres and is successfully exploiting cross-selling potential. By the end of the year, the services of “M1 Laser” are to be offered in almost all German locations. Based on this positive business development, M1 Kliniken has confirmed its operating targets for 2019: Double-digit increase in Group sales and earnings. In the second half of 2019, numerous new locations in Germany and abroad will be added and will contribute to the Group’s operational growth in the future.

HAEMATO AG has approved a dividend of EUR 0.10 per share for 2018. The product portfolio is currently being realigned and internal processes optimized and digitized. The pharmaceutical company, which focuses on the growth markets of high-priced special pharmaceuticals, is currently establishing new personnel and digital structures in product management, procurement and sales in order to exploit the existing market potential more extensively in the future. As expected, the company’s operating performance in the first half of the year was significantly below the previous year’s level. HAEMATO achieved sales of EUR 94.0 million and earnings before interest and taxes (EBIT) of EUR 0.7 million. After HAEMATO adjusted its product portfolio for low-margin products last year, capacities are now available for the introduction of new products. This includes the trading of narcotics (including medical cannabis) and the development of medical products. This means broadening the product range in segments with above-average growth.

Go back